Alaunos Therapeutics Inc TCRT:NASDAQ

Last Price$1.24NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change0.00(0.00%)
Bid (Size)$1.21 (8)
Ask (Size)$1.26 (3)
Day Low / High$1.15 - 1.26
Volume1.7 M

View Biotechnology IndustryPeer Comparison as of 06/30/2022


Alaunos Therapeutics Inc ( NASDAQ )

Price: $1.24
Change: 0.00 (0.00%)
Volume: 1.7 M
4:00PM ET 6/30/2022

Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.58
Change: -0.03 (1.86%)
Volume: 785.1 K
8:00PM ET 6/30/2022

Scholar Rock Holding Corp ( NASDAQ )

Price: $5.49
Change: +0.07 (1.29%)
Volume: 824.1 K
4:00PM ET 6/30/2022

Precigen Inc ( NASDAQ )

Price: $1.34
Change: -0.02 (1.47%)
Volume: 713.3 K
4:00PM ET 6/30/2022

Epizyme Inc ( NASDAQ )

Price: $1.47
Change: 0.00 (0.00%)
Volume: 4.5 M
4:00PM ET 6/30/2022

Read more news Recent News

US Futures Mixed Ahead of Inflation Data
8:38AM ET 6/10/2022 MT Newswires

US stock futures are mixed during Friday's premarket session ahead of monthly inflation figures, with the Consumer Price Index for May expected to rise...

Top Premarket Gainers
7:59AM ET 6/10/2022 MT Newswires

Rise Education Cayman (REDU) gained more than 240% after a change its American depositary shares ratio to 10 shares per ADS from 2 shares became effective...

--Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight
7:22AM ET 5/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Alaunos Therapeutics Doses First Patient in Phase 1/2 Trial of TCR-T Cell Therapy in Solid Tumors
10:49AM ET 5/02/2022 MT Newswires

Alaunos Therapeutics (TCRT) said Monday it has dosed the first patient in a phase 1/2 trial of TCR-T cell therapy for patients with solid tumors. The...

Company Profile

Business DescriptionAlaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. View company web site for more details
Address8030 El Rio Street
Houston, Texas 77054
Number of Employees48
Recent SEC Filing06/27/20228-K
Chief Executive Officer & DirectorKevin S. Boyle
Executive Vice President-OperationsEleanor M. de Groot
Chief Financial OfficerTimothy M. Cunningham
Vice President-Research & DevelopmentDrew Deniger

Company Highlights

Price Open$1.20
Previous Close$1.24
52 Week Range$0.41 - 2.75
Market Capitalization$267.8 M
Shares Outstanding216.0 M
SectorHealth Technology
Next Earnings Announcement08/12/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.30
Beta vs. S&P 500N/A
Revenue$146.0 K
Net Profit Margin-16,830.40%
Return on Equity-101.43%

Analyst Ratings as of 05/03/2022

Consensus RecommendationConsensus Icon
Powered by Factset